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Update on the EFFECTS study of fluoxetine
for stroke recovery: a randomised
controlled trial in Sweden
Erik Lundström1* , Eva Isaksson2, Per Näsman3, Per Wester4,5, Björn Mårtensson6, Bo Norrving7, Håkan Wallén8,
Jörgen Borg4, Martin Dennis9, Gillian Mead9, Graeme J. Hankey10, Maree L. Hackett11,12,
Katharina S. Sunnerhagen13,14,15,16 and For the EFFECTS Trial Collaboration
Abstract: Studies have suggested that fluoxetine might improve neurological recovery after stroke, but the results
remain inconclusive. The EFFECTS (Efficacy oF Fluoxetine – a randomisEd Controlled Trial in Stroke) reached its
recruitment target of 1500 patients in June 2019. The purpose of this article is to present all amendments to the
protocol and describe how we formed the EFFECTS trial collaboration in Sweden.
Methods: In this investigator-led, multicentre, parallel-group, randomised, placebo-controlled trial, we enrolled non-
depressed stroke patients aged 18 years or older between 2 and 15 days after stroke onset. The patients had a
clinical diagnosis of stroke (ischaemic or intracerebral haemorrhage) with persisting focal neurological deficits.
Patients were randomised to fluoxetine 20 mg or matching placebo capsules once daily for 6 months.
Results: Seven amendments were made and included clarification of drug interaction between fluoxetine and
metoprolol and the use of metoprolol for severe heart failure as an exclusion criterion, inclusion of data from
central Swedish registries and the Swedish Stroke Register, changes in informed consent from patients, and
clarification of design of some sub-studies.
EFFECTS recruited 1500 patients at 35 centres in Sweden between 20 October 2014 and 28 June 2019. We plan to
unblind the data in January 2020 and report the primary outcome in May 2020.
Conclusion: EFFECTS will provide data on the safety and efficacy of 6 months of treatment with fluoxetine after
stroke in a Swedish health system setting. The data from EFFECTS will also contribute to an individual patient data
meta-analysis.
Trial registration: EudraCT 2011-006130-16. Registered on 8 August 2014.
ISRCTN, ISRCTN13020412. Registered on 19 December 2014.
ClinicalTrials.gov: NCT02683213. Retrospectively registered on 2 February 2016.
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Introduction
Background
Globally, 13.7 million new strokes occur annually [1]. In
Sweden, with a population of about 10 million inhabi-
tants, about 23,000 people experience stroke annually
[2]. Despite major improvements in the treatment of
acute ischaemic stroke over the past 20 years, about half
of all stroke survivors are left with long-term residual
disability [3].
In 2011, the FLAME trial [4] reported promising re-
sults for the effects of fluoxetine on stroke recovery.
FLAME was a randomised controlled trial (RCT) of 118
patients with ischaemic stroke and unilateral motor
weakness; half of the patients were randomised to 20 mg
fluoxetine and half to placebo daily for 3 months as well
as receiving physiotherapy. At 3 months, the proportion
of patients with a modified Rankin Scale (mRS) [5] of 0–
2 was 17 absolute percent higher in the fluoxetine group
(26% versus 9%, p = 0.015). A subsequent Cochrane re-
view of 52 RCTs (N = 4059) of selective serotonin re-
uptake inhibitors (SSRIs) for stroke recovery [6] showed
that SSRIs improved functional recovery after stroke.
However, most trials were small and prone to systematic
and random errors. The authors concluded that large,
well-designed trials were needed to determine whether
SSRIs were indeed safe and effective in improving func-
tional outcome after stroke.
This led us to develop a family of three large trials of
fluoxetine for stroke recovery [7]: EFFECTS (Efficacy oF
Fluoxetine – a randomisEd Controlled Trial in Stroke),
AFFINITY (The Assessment oF FluoxetINe In sTroke
recovery) and FOCUS (Fluoxetine Or Control Under
Supervision) [8]. Each trial was funded and run separ-
ately with oversight from its own Steering Committee.
We hypothesised that the routine administration of 20
mg fluoxetine once daily in the 6 months after an acute
stroke improves the patient’s functional outcome.
The FOCUS trial (N = 3127) is the only trial to date to
have finished and published its results [8]. For the
primary outcome measure, the distribution across mRS
categories at 6 months was similar in the fluoxetine and
placebo groups (common odds ratio adjusted for mini-
misation variables 0.95 [95% CI 0.84–1.08]; p = 0.44).
Patients allocated fluoxetine were less likely than those
allocated placebo to develop new depression by 6
months (13.4% vs 17.2%, p = 0.0033), but they had more
bone fractures (2.9% vs 1.5%; p = 0.007).
The EFFECTS (N = 1500) and AFFINITY (N = 1280)
trials finished their recruitment in June 2019 and are
due to report their primary outcome at the stroke con-
ference jointly organised by the European Stroke Organ-
isation and the World Stroke Organization in Vienna in
May 2020. Further, we plan to present an individual pa-
tient data meta-analysis from the three trials. Finally, we
will combine our data and update the Cochrane system-
atic review of selective serotonin reuptake inhibitors
(SSRIs) for stroke recovery [6].
This update follows the Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) 2013
checklist [9] in combination with the 2013 SPIRIT
explanation and elaboration guidance for protocols of
clinical trials [10] (Additional files 1 and 2).
The purpose of this update is to present all amend-
ments to EFFECTS and describe how we formed the
EFFECTS trial collaboration. We also describe the set-
tings and locations in which the study was performed.
Methods
Design overview
EFFECTS is a multicentre, randomised, placebo-controlled,
blinded, parallel group trial of fluoxetine for stroke recovery
performed at 35 centres in Sweden. Primary outcome was
the mRS at 6months. Recruitment started 20 October 2014
and ended 28 June 2019, when the target of 1500 patients
was met. We plan to unblind the dataset when the last pa-
tient has had their 6-month follow-up in January 2020 and
report the primary outcome in May 2020.
For description of the core study protocol, including
study procedures and data collection, allocation and
blinding procedures, we refer to the published trial
protocol publication [7] and statistical analysis plan [11].
Important changes after trial commencement
During the course of the study, we made seven amend-
ments to the protocol. All these amendments, the Re-
search Ethical Committee approvals and the approvals
from the Swedish Medical Product Agency are available
in Additional file 3. For convenience, we have sum-
marised the amendments and their justification in a
table (Additional file 4).
The latest version of the protocol (version 5.0 28 Feb-
ruary 2018) is available online on the study’s website
[12]. All previous versions including amendments were
published on the homepage and communicated to active
centres during the course of the study.
Below, we list the two most important changes.
1. In Amendment 2, we changed the patient consent
form. In this version, the patient permits EFFECTS
to obtain information from the central Swedish
registries regarding sick leave, care-related con-
sumption of resources and survival. Registry data
are more accurate when collecting health econom-
ics data than asking patients for this information
[13]. In this way, the responder burden for patients
was reduced.
Amendment 2 was approved 10 June 2015. All
patients who had signed the old consent form (25
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April 2013, v 2), had to re-sign the new version (18
May 2015, v 3). On 25 May 2018, the General Data
Protection Regulation (GDPR) was implemented.
Since GDPR is a regulation governed by EU law, we
had to change the consent form, which is reflected
in v 4, 25 May 2018 (Additional file 5). This change,
however, was not accompanied by any amendment
or re-signing of consent. We informed all patients
who had signed the previous consents via a personal
letter and updated our homepage with the
information.
2. About safety. The company that manufactured our
Investigational Medicinal Product, informed us on
22 November 2016 that they had updated their
Summary of Product Characteristics. EFFECTS
Steering Committee and Data Monitoring
Committee concluded that a serious interaction
between metoprolol and fluoxetine may be clinically
significant for more advanced heart failure.
Consequently, we added the following exclusion
criteria:
“Fluoxetine is contra-indicated in combination with
metoprolol used in cardiac failure New York Heart
Association Grade III B–IV.”
Further, we clarified that patients treated with
higher doses of metoprolol (> 100 mg/day) on the
indication of heart failure, early after enrolment,
should be monitored clinically and with an
electrocardiogram.
For safety reasons, we carried out a review of the
medical charts of patients currently on metoprolol.
Our Data Management Committee did not find any
indication of serious interaction after reviewing the
unblinded data and advised the Chief Investigator
and the Steering Committee to carry on.
Amendment 5. Approval 4 January 2017.
Settings and locations where the data were collected
EFFECTS is performed in Sweden in which the health
care is tax funded and fairly equally distributed through-
out the country [14]. The government establish princi-
ples and guidelines, and sets the political agenda for
health and medical care. Sweden is divided into 20 re-
gions, each responsible for the health care in its particu-
lar area. In Sweden, hospitals can be divided in three
types: university hospitals, specialised non-university
hospitals, and community hospitals [15]. There is acute
stroke care in all these, in total, 72 hospitals.
Stroke in Sweden data from Riksstroke 2018
In 2018, there were 21,124 strokes registered in
Riksstroke – the Swedish stroke registry [2]. With a
coverage of 90% of all strokes the estimated number of
strokes is 23,735.
Ischaemic stroke accounts for 86% and intracerebral
haemorrhage for 14%. In 2018, 63% had mild strokes,
defined as National Institutes of Health Stroke Scale
(NIHSS) 0–5 points. The mean NIHSS was 6 and the
median 3 points.
More men (54%) than women (46%) have a stroke.
The mean age is 75 years, 73 for men and 78 for women.
Sixty-four per cent of the stroke patients have high
blood pressure, 29% atrial fibrillation, 23% diabetes and
14% are smokers at onset.
Standard care of stroke in Sweden
In 2018, 17% of all patients with ischaemic stroke were
treated with reperfusion therapy; 14% with intravenous
thrombolysis only, or intravenous thrombolysis in com-
bination with thrombectomy. Reperfusion treatment has
almost tripled since 2010.
The proportion of acute stroke patients treated at a
stroke unit at some point during their hospital stay is high
– 92%. The median length of stay in hospital is 7 days, with
substantial variation between the hospitals. One reason for
the variation could be different application of early sup-
ported discharge. Approximately 85% of patients are evalu-
ated by a physical or occupational therapist, and around a
third of the patients had their speech and swallow function
evaluated by a speech therapist during the hospital stay.
Three out of four return to their own home after dis-
charge. Of those one in four are judged to have no need
of any rehabilitation, according to staff at the dis-
charging hospital.
In EFFECTS, we did not give any specific instructions
to health-care personnel regarding physical or other
types of training, although the local centre registered,
organised and individualised training for each patient.
Patients received stroke rehabilitation according to their
local stroke team’s routines during the treatment period.
Results
Building a network, training the study personnel and
initiation of sites
Early in the process we decided to meet potential inves-
tigators at their hospitals face to face instead of relying
on email or telephone. This decision was based on intu-
ition rather than a review of the literature and it led to
more than 100 travelling days for the chief investigator
and the trial manager.
How we reached out to a potential centre
First, we reached out to people we have previously worked
with in the International Stroke Trial 3 [16]. This was
done by a brief email about the rationale behind EF-
FECTS, an estimate of the time commitment, and the fi-
nancial compensation for participation in the study. If the
centre was interested in joining the trial, the principal
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investigator (PI) at each centre sent in an Expression of
Interest/Eligibility form and we scheduled a Site Initiation
Visit (SIV) as soon as possible. The SIV was described as
an information meeting and was carried out during lunch-
time. All staff at the stroke unit, and where appropriate,
outpatient service, were welcomed to participate in the
SIV, but it was mandatory for the intended PI and the trial
nurse. For the PI and trial nurse, the meeting could last
from 1 to 3 hours, depending on how familiar the centre
was with RCT participation.
Second, we used the Riksstroke report to identify
Stroke Units with medium to high volume care. If a
centre had been awarded Stroke Unit of the Year, or re-
ceived an Excellent Stroke Care mention in Riksstroke,
we contacted the centre, regardless of its size.
Third, we attended several stroke meetings in Sweden
and one Nordic Stroke Meeting (held in Malmö,
Sweden) with an EFFECTS exhibition (Table 1).
Finally, on two occasions, we carried out feasibility
studies in which we examined whether eligible patients
and interested study personnel were available.
The study personnel were not given any personal monet-
ary compensation. The centre, however, received 5000 SEK
for each included patient. There was no upper limit to how
many patients the centre could include. The EFFECTS study
was done in parallel with the usual health care in Sweden.
All patients were covered by the Swedish medical in-
surance [17].
Site initiation visit
All personnel – during a working lunch meeting
(1 hour) The following items were discussed with the sites:
 The rationale, scientific background and hypothesis.
(Chief investigator, approximately 20 minutes)
 Inclusion and exclusion criteria. Follow-up. Brief
introduction to randomisation and follow-up. (Trial
manager, approximately 20 minutes)
 Questions and answers (All, 20 minutes)
PI and trial nurse(s) – extended meeting after the
lunch (1–3 hours) After the lunch, the trial manager
and the chief investigator discussed the following in
detail:
 Study protocol
 Procedure for informed consent
 Patient recruitment plan/screening activities/
enrolment
 Facilities and study personnel
 Randomisation procedure
 Investigational Medicinal Product handling and
accountability
 Essential documents
 How the Case Report Form is filled out
 Safety reporting (adverse events/serious adverse
events) and procedures for collection and
documentation
 Good Clinical Practice (GCP) training and
curriculum vitae
Finally, the Investigator Study File was handed over
and discussed. The Investigator Study File contained es-
sential documents required according to GCP. After all
essential documents were signed and sent to the co-
ordinating centre the study personnel (listed in the
delegation log) were given access to the randomisations
system and the centre was approved as active, ready to
recruit patients.
Time for the local centre
Table 1 illustrates the time commitment for a typical
patient and their follow-ups at the local centre.
Organisation and training of an EFFECTS centre
At each centre, we established a delegation list and per-
sons on that list are referred to as study personnel. The
study personnel consisted of a minimum of two people:
one principal investigator (an experienced stroke phys-
ician) and one responsible trial nurse (registered nurse),
both trained in GCP, the trial-specific procedures and
our electronic Case Report Form (eCRF).
Further co-investigators (physicians) or trial nurses
(registered nurses) were added at the discretion of the
local principal investigator. We had no upper limit on
how many study personnel were allowed on the delega-
tion list, but all people who performed study-specific
tasks had to be trained in GCP, study-specific instru-
ments and eCRF. The training was organised by the co-
Table 1 Estimated time/patient required for the local centre
Item Time
Screening 5 min
Inclusion 60 min
1 week telephone follow-up 5 min
1 month telephone follow-up 5 min
3 months follow-up (face-to-face; sometimes
by telephone)
30 min
6 months follow-up, face-to-face 60 min
7 months telephone follow-up 30 min
Entering data into the electronic case report system 60min
Answering queries 60 min
Other: We arranged training for the study personnel in study specific
moments (4 h) and Good Clinical Practice (4 h). In addition, we
organised 4 investigator meetings in Sweden (1 day per meeting) and 5
meetings at European Stroke Conferences.
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ordinating centre at Karolinska Institutet, either at the
local site or at special central training days. In total, we
trained over 150 study personnel in EFFECTS. A list of
all centres and study personnel is available as Additional
file 6.
EFFECTS recruited patients from acute stroke and re-
habilitation units. Around 3% of Swedish stroke patients
go to a rehabilitation unit.
The reason for recruiting from rehabilitation units was
that the median length of stay in hospital in Sweden is
short – especially in the Stockholm region – and since it
was possible to include patients until 15 days post stroke,
we thought it would be possible to include individuals at
rehabilitations units.
Discussion
EFFECTS proves that it is possible to carry out a large
investigator-led RCT in a country with only 10 million
inhabitants. In fact, EFFECTS is now the largest ever
stroke RCT conducted in Sweden. Further, EFFECTS is
the second largest RCT of fluoxetine for stroke recovery
after the FOCUS trial [8].
As a family of three investigator-led RCTs, EFFECTS,
AFFINITY and FOCUS provide several benefits. To-
gether, we wrote a strong core protocol and applied for
funding in our respective countries and tailored study
methods to each national setting(s). EFFECTS was able
to use the same randomisation system and purchase the
study drug from the same provider as FOCUS, which
saved months of work. However, most important of all
was probably the transfer of knowledge from expe-
rienced trialist to less experienced.
Although EFFECTS succeeded in reaching its target of
1500 participants, one major limitation was that it took
longer than anticipated. We believe that the lack of a
stroke research network was the main culprit. While we
were able to build on an old informal network from the
International Stroke Trial 3 (IST-3) [18], in many cases
the previous PI or trial nurse had retired or moved. Ba-
sically, we had to build up and train our own stroke re-
search network from scratch. In the United Kingdom,
where there is a centrally funded network to support tri-
als, our sister study FOCUS proved that recruitment
rates were faster.
Data from EFFECTS will test the external validity of
the FOCUS trial results and increase the precision of the
estimates of the efficacy and safety of fluoxetine in is-
chaemic and haemorrhagic stroke. The planned individ-
ual patient data meta-analysis of EFFECTS, AFFINITY
and FOCUS [8], as well as a subsequent update of the
Cochrane systematic review [6] will likely give us a
definitive answer as to whether fluoxetine has any role
to play in stroke recovery.
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Management
Co-ordination centre
The co-ordination centre was located at Karolinska Institutet Department of
Clinical Sciences Danderyd Hospital, and those responsible for the day-to-
day management were chief investigator Erik Lundström, trial manager Eva
Isaksson and trial manager assistant Nina Greilert.
Steering Committee’s responsibilities
The Steering Committee is responsible for following the development of the
study, assisting the chief investigator with advice and support when
required.
The Steering Committee is also responsible for:
1. Ensuring that the protocol for the study is followed.
2. Policies, superior organisational issues and any technical issues.
3. Analysing the reports from the Data Management Committee.
4. Monitoring finances in collaboration with Karolinska Institutet, which is the
financial manager and manages the funds.
5. Overseeing staff; however, Karolinska Institutet has the responsibility for
personnel.
6. Considering the need for any protocol changes.
7. If any sub-studies are planned within the framework of the main study,
they should be presented orally first, on condition that the Steering Commit-
tee considers the study to be feasible and scientifically sound, and that it
does not affect the main study. A written project report has to be submitted
and approved by the Steering Committee before any application is sent. A
signed (by the chair of the Steering Committee after approval by the Steer-
ing Committee) project plan should be filed at Karolinska Institutet. When
submitting an application for ethics approval or funds, the chair of the Steer-
ing Committee and the chief investigator should be informed of this before
submission. No changes may be made to an approved protocol without this
being approved and signed in accordance with the conditions presented
above.
Members of the Steering Committee
The Steering Committee consists of Professor Katharina Stibrant
Sunnerhagen (chair), Professor Per Wester, Professor Bo Norrving, Professor
Håkan Wallén, Senior Professor Jörgen Borg, Senior Associate Professor Björn
Mårtensson, Associate Professor/statistician Per Näsman, chief investigator/
Associate Professor Erik Lundström, and trial manager Eva Isaksson. The co-
chief investigators from FOCUS and AFFINITY were affiliated to the Steering
Committee. We have not had any patient involvement in the Steering Com-
mittee nor when we wrote the protocol.
Monitoring of EFFECTS
Most of the monitoring was carried out centrally, however, online onsite
monitoring and detailed source data verification by Karolinska Trial Alliance
was also carried out (Additional file 7).
External monitoring by Karolinska Trial Alliance
Regular onsite monitoring visits were performed during the study
depending on the enrolment rate and according to a specific monitoring
plan.
Monitoring was performed according to ICH-GCP, Declaration of Helsinki,
CRO SOPs for monitoring and the monitoring plan.
The first routine study monitoring visit was performed at each site when a
few patients were randomised into the study, to confirm informed consent
procedure, subject eligibility, ensure that the site was familiar with study
drug management, detect possible problems and provide advice on how to
complete the eCRF.
Source data verification was performed according to the monitoring plan
throughout the study. The monitor ensured that 100% of all patients had
signed the informed consent and verified that essential documents were
available and up to date in the Investigator Study File continuously during
the study. In addition, the external monitors carried out a 10% source data
verification and drug accountability.
After each monitoring visit, the monitor sent a report to the sites and a copy
of the report to the co-ordinating centre at Karolinska Institutet, and the rep-
resentative for the sponsor. The report included a summary of the monitor-
ing and highlighted issues that need to be followed up by the sites.
Close-out visit:
When the last patient has completed the study or when a site has been
closed in advance, the monitor carried out a close-out visit at each site. At
this visit the following were discussed:
• Possible remaining unsolved eCRF queries
• Investigator Study File completeness
• Possible remaining unresolved issues
• Patients: screened, randomised and complete
• Study drug accountability log completed
• Safety reporting (adverse events/serious adverse events)
• Information to study team regarding study report and archiving
Study drugs returned by the patients and remaining study drugs at the sites
were sent for destruction to Apoteket AB, Sweden.
Dissemination policy
The Steering Committee ensured that a good publication policy was applied
to the protocol, which states that publications are prepared by persons
approved by the Steering Committee. The study is dependent on
collaboration with a large number of doctors, nurses, patients and relatives.
Those included in the local centre (who were on the delegation list) were
included in a list (Additional file 6). The publication was prepared by a
writing committee following the current International Committee of Medical
Journals Editors Recommendations [19].
Data management and data cleaning
The task of data management, quality and integrity was shared by the
centres, co-ordination centre at Karolinska Institutet, Karolinska Trial Alliance
and personnel from EDC Scandinavia AB (Additional files 8 and 9).
We used OpenClinica® as our eCRF. Data entries in the eCRF were done at
each at centre. Almost all variables in our eCRF have mandatory checks for
inconsistent values.
In addition, there is an audit trail and the possibility to send queries within
the system.
The data cleaning process was carried out by the co-ordination centre at Kar-
olinska Institutet and began when the first 500 patients had finalised their
12-month follow-up. The process was ongoing until the last patient was
followed up.
All central follow-ups at 6 and 12 months were mailed out from the co-
ordination centre. If the study subjects did not return their questionnaire, we
reminded the patient by telephone; then the patient either returned the
questionnaire or more often the patient gave their answers over the
telephone.
All follow-up forms were processed by a research assistant, and another re-
search assistant cross-checked 100% of the primary outcome (smRSq) and
10% of data.
Confidentiality
All study-related information was stored securely at the local centre in locked
filing cabinets in areas with limited access. All reports, data collection, pro-
cesses and administrative forms are identified by an EFFECTS trial ID number
to maintain patients’ confidentiality. All records that contain names or other
personal identifiers, such as informed consent forms, are stored separately
from study records identified by code number. The central database is lo-
cated at a secure server with password-protected access systems. Forms, lists,
logbooks, appointment books, and any other listings that link participant ID
numbers to other identifying information are stored in a separate, locked file
in an area with limited access as well as in Karolinska Institutet’s electronic
notebook [20].
Access to data
The final cleaned data set will be saved in Karolinska Institutet’s electronic
notebook [20]. Trial statistician (PN) and chief investigator (EL) will have
access to the data. A limited number of variables will be shared with the
FOCUS and AFFINITY trials enabling the planned individual patient data (IPD)
meta-analysis. All data will be stored anonymised, using the EFFECTS trial ID.
Details of assessment and collection as well as processes to promote data
quality can be found in the (Additional files 8 and 9).
Data collection forms (in Swedish) can be found on our homepage, www.
effects.se.
In summary, the responsibilities were divided up as follows:
Database design EDC Scandinavia
eCRF design EDC Scandinavia, Co-ordination Centre
at Karolinska Institutet and Karolinska
Trial Alliance
Server management EDC Scandinavia
Data collection Centre and Co-ordination Centre at
Karolinska Institutet
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Data manager EDC Scandinavia
CRF annotation Centre, Co-ordination Centre at Karo-
linska Institutet and Karolinska Trial
Alliance
Data entry Centre, Co-ordination Centre at Karo-
linska Institutet and Karolinska Trial
Alliance
Monitoring Karolinska Trial Alliance
Source data verifications Karolinska Trial Alliance
Issue and resolve data correction
forms
Co-ordination Centre at Karolinska
Institutet and Karolinska Trial Alliance
Medical coding Co-ordination Centre at Karolinska
Institutet
Data validation EDC Scandinavia and Co-ordination
Centre at Karolinska Institutet
Discrepancy management Centre, Co-ordination Centre at Karo-
linska Institutet and Karolinska Trial
Alliance
Database lock. The database will be
preserved according to Karolinska
Institutet’s rules, the electronic
notebook [20].
EDC Scandinavia
Data Monitoring Committee
The Data Monitoring Committee (DMC) independently monitored patient
safety and efficacy information during the trial (Additional file 10). The DMC
comprised of two experienced stroke physicians: Senior Professor Kjell
Asplund (chair), Senior Associate Professor Kerstin Hulter Åsberg, and a
biostatistician, Anders Ljungström.
DMC members were not involved as principal investigators or sub-
investigators in the study. In addition, DMC members were not allowed to
have a conflict of interest that would bias their review of trial data (e.g. finan-
cial interests that could be substantially affected by the outcome of the
study, strong views on the relative merits of the study drug, relationships
with individuals in trial leadership positions that could be considered reason-
ably likely to affect their objectivity, or involvement in any potential compet-
ing trial).
The unblinded statistician – Anders Ljungström – prepared data and reports
for the DMC to review. The chief investigator served as a primary contact
person for the DMC and DMC issues.
Review meetings for the DMC
The DMC chairman ensured that DMC contacts and consultants were not
inappropriately exposed to unblinded data made available to the DMC.
The DMC was an independent expert advisory group commissioned and
charged with the responsibility for evaluating cumulative safety, efficacy and
other clinical trial data at regular intervals. As such, the primary objective of
the DMC was to monitor the safety of the subjects in the study by reviewing
the available clinical data at scheduled time points including at least yearly
meetings (which may be face to face or via teleconference) and on an ad
hoc basis as required.
After the review of each data report was completed, the DMC chair provided
the official DMC recommendation to the sponsor, the chief investigator and
the chair of the Steering Committee regarding the appropriateness of
continuing the study, from a safety and efficacy perspective, as well as any
other recommendations relevant to study conduct and/or patient safety.
Specifically, the DMC members were authorised and expected to perform
the following functions:
• Safeguard the interests of trial participants.
• Provide approval for and operate in accordance with the specifications
outlined in the DMC Charter.
• Monitor the safety and efficacy of the trial intervention, through scheduled
review of accumulating clinical data from the EFFECTS study and taking into
account information from external sources.
• Consider the need for additional unscheduled reviews of study data.
• Review and evaluate the content of all unblinded data reports received.
• Ensure the confidentiality of all information received relating to the trial.
• In the event of further funding being required, to provide the Steering
Committee and funder(s) with appropriate information and advice on the
data gathered to date in a manner that will as far as possible protect the
integrity of the study.
• Participate in and vote on DMC recommendations, bearing in mind the
fact that ethical considerations are of prime importance.
• Make clear recommendations to the Steering Committee, with the Steering
Committee chair as the principal contact.
• The DMC reviewed safety outcomes, including serious adverse events.
Review of safety data occurred after 150, 300, 600, 900 and 1200 patients’ 6-
month follow-up data. No formal boundaries were used for terminating the
study for safety reasons, but clear and consistent evidence of net harm that
overrides any benefit should be apparent.
• A formal interim analysis to assess efficacy was done when approximately
67% of the planned primary efficacy events had accrued. The DMC was able
to recommend early termination of the trial for the overwhelming
superiority of fluoxetine over control. A modified Haybittle-Peto monitoring
boundary was used as a guideline. If the primary efficacy comparison ex-
ceeds four standard errors in value, the DMC will initiate another interim ana-
lysis to be performed a minimum of 3 months later. If the monitoring
boundary remains crossed, the DMC may recommend that the trial for the
overwhelming superior efficacy of fluoxetine be terminated early. No adjust-
ment of the significance level for the final analysis is required.
The DMC did not make any recommendations on whether the trial should
be stopped on the basis of futility, i.e. that the trial – if it recruits to its target
sample size – is unlikely to demonstrate a benefit from the trial of fluoxetine.
Throughout the trial, the DMC chair took responsibility for the committee’s
operations and authorised and assigned the following responsibilities:
• Chair DMC data review meetings.
• Ensured that all relevant data have been reviewed by the DMC members
and that all issues have been addressed.
• Ensured that blinded individuals (i.e. the DMC coordinator, DMC contacts,
and DMC consultants) were not inappropriately exposed to confidential and/
or unblinded data.
• Ensured that only the members of the DMC were present during DMC
deliberations, when DMC recommendations were discussed, and DMC
voting procedures were conducted.
• Ensured the generation of confidential, written minutes of all closed
sessions of any DMC meetings and maintained these minutes as confidential
to DMC members only, until the final (end of study) database lock was
completed.
• Ensured DMC approval of minutes of open and final sessions of all DMC
meetings.
• Communicated, authored, signed, and provided the official, final
recommendations of the DMC within specified timelines and according to
the specifications outlined in the charter. If the DMC was divided in opinion
on any major issue affecting the DMC’s recommendation to the sponsor and
EFFECTS Steering Committee, the DMC chair was responsible for assembling
and presenting the majority and dissenting opinions for all
recommendations considered.
• Arranged for consultation(s) and/or request additional data, as deemed
necessary.
• If deemed appropriate by the DMC, at appropriate intervals, arrange a
teleconference meeting with the chairs of the DMC committees for the
FOCUS (Professor Peter Langhorne) and AFFINITY (Professor Robert Herbert,
Australia) trials. If necessary, to discuss accumulating data in strict confidence
and any implications for the continuation of each of the trials. Each chair
may then subsequently need to consider whether to arrange a meeting of
their respective trial DCM to discuss any issues that may arise from this
liaison group.
• Maintain a secure central file of all data outputs received for DMC review
and all minutes of all sessions of DMC meetings. Provide the sponsor with a
copy of this file, through the chief investigator, once the final (end of study)
database lock is complete.
Principal Investigator at each centre
At each participating centre, a PI is responsible for identification, recruitment,
data collection and completion of CRFs, along with follow-up of study pa-
tients and adherence to the study protocol and the investigators’ brochure.
The PI is not part of the Steering Committee.
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